Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Zevra TherapeuticsJohnson & Johnson
Last price
$10.73$254.78
Currency
USD
USD
$635M$610B
12.1329.32
$0.88$8.63
0.950.23
0$5.28
02.12%
Sector
HealthHealth
Employees
61138,200
Ticker
$ZVRA$JNJ
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $ZVRA or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.